Figure 3 | British Journal of Cancer

Figure 3

From: Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Figure 3

Mean asparagine–glycine–arginine–human tumour necrosis factor (NGR-hTNF) Cmax (A) and doxorubicin AUC (B) during the first three cycles by dose level. Mean plasma concentrations of soluble TNF receptors tumour necrosis factor receptor I (TNF-RI) (C) and tumour necrosis factor receptor II (TNF-RII) (D) during the first cycle by dose level. Abbreviations: Cmax, maximal plasma concentration; AUC, area under the plasma concentration vs time curve up to the last detectable concentration.

Back to article page